<DOC>
	<DOC>NCT00440141</DOC>
	<brief_summary>Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%</brief_summary>
	<brief_title>Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%</brief_title>
	<detailed_description />
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Glaucoma or ocular hypertension in both eyes Currently being treated with latanoprost 0.005% QD IOP greater than or equal to 18mm Hg on latanoprost 0.005% Bestcorrected VA of 20/200 or better in each eye Visual field within 6 months of study entry Secondary glaucoma Active intraocular inflammation or macular edema Intraocular surgery or laser surgery within the past 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>